Company Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.
It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors.
The company’s CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB.
Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
| Country | United States |
| Founded | 2016 |
| IPO Date | Sep 25, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 131 |
| CEO | Krishna Vaddi |
Contact Details
Address: 175 Innovation Boulevard Wilmington, Delaware 19805 United States | |
| Phone | 302 467 1280 |
| Website | preludetx.com |
Stock Details
| Ticker Symbol | PRLD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001678660 |
| CUSIP Number | 74065P101 |
| ISIN Number | US74065P1012 |
| Employer ID | 81-1384762 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Krishna Vaddi D.V.M., Ph.D. | Founder, Chief Executive Officer and Director |
| Dr. Edna Huang M.D. | President and Chief Medical Officer |
| Bryant David Lim J.D. | Chief Financial Officer, Chief Legal Officer and Corporate Secretary |
| Aimee Crombie Ph.D. | Senior Vice President and Head of Strategic Planning and Operations |
| Dr. Madhu Pudipeddi Ph.D. | Senior Vice President of Technical Operations |
| Dr. Peggy A. Scherle Ph.D. | Chief Scientific Officer |
| Michele Porreca M.B.A. | Chief People Officer |
| Dr. Andrew P. Combs Ph.D. | Executive Vice President and Chief Chemistry Officer |
| Naveen Babbar Ph.D. | Senior Vice President of Translation Medicine |
| Dr. William B. Novotny M.D. | Senior Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 6, 2025 | 10-Q | Quarterly Report |
| May 6, 2025 | 8-K | Current Report |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 25, 2025 | 8-K | Current Report |
| Apr 11, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 28, 2025 | 8-K | Current Report |
| Mar 10, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |